Photocontrolled nanosystem potentiates photo-chemoimmunotherapy against TNBC by integrating apoptosis/ferroptosis/ pyroptosis and STING activation Authors: Pan Zhang, Minglun Liu, Lei Huang, Zijie Zhao, Qianqian Zhang, Yunhao Li, Yuncong Chen, Lili Liang Published: 2026 ABSTRACT AbstractTriple-negative breast cancer (TNBC) frequently exhibits profound chemoresistance and a highly immunosuppressive tumor microenvironment (TME), leading to suboptimal clinical outcomes with high risks of early recurrence and distant metastasis. Existing monotherapies remain inadequate in disrupting these therapeutic barriers. To overcome the aforementioned obstacles, we developed a spatiotemporally regulated organelle-targeted nanoplatform, IR820-GEM@MIL101 (IGM), Its design aims to achieve precise mitochondrial intervention and coordinate cGAS–STING-mediated immune activation. This design relies on EPR-mediated passive targeting to achieve preferential tumor accumulation, allowing IGM to accumulate specifically in tumor tissues and trigger a series of reactions in response to endogenous stimuli (acidic pH and elevated glutathione) in synergy with exogenous near-infrared laser activation, enabling controlled drug release. The platform efficiently eliminates tumor cells by inducing multiple modes of cell death, including pyroptosis, ferroptosis, and apoptosis, while simultaneously triggering immunogenic cell death (ICD) and activating the cGAS–STING pathway. This dual immunostimulatory strategy effectively converts “cold” tumors into “hot” tumors. In a bilateral tumor model, IGM treatment increased CD8+ T-cell infiltration in distal tumors by 94% and achieved a tumor inhibition rate of 92.7% in distant lesions. This work shifts the therapeutic focus from superficial multi-drug packaging to precise organelle-targeted intervention, providing a promising strategy for light-regulated combinatorial immunotherapy against aggressive malignancies.Keywords: Photoimmunotherapy, Ferroptosis, Pyroptosis, Gemcitabine, Triple-negative breast cancer Introduction As a highly invasive malignant tumor, triple-negative breast cancer (TNBC) poses a severe threat to women's health worldwide, with its clinical management long plagued by intractable challenges. Conventional first-line treatments such as surgery and radiotherapy fail to effectively control tumor recurrence and distant metastasis. Although chemotherapy serves as a systemic therapeutic modality, its efficacy is severely compromised by inherent chemoresistance in tumor cells and systemic toxicity of chemotherapeutic agents, resulting in poor patient prognosis [1,2]. In recent years, the advent of immunotherapy has revolutionized the therapeutic landscape of TNBC. Clinical studies have confirmed that chemotherapy combined with immune checkpoint inhibitors (ICIs) can elicit synergistic antitumor effects [[3], [4], [5]]. Nevertheless, chemoresistance derived from the high heterogeneity of TNBC, the immunosuppressive nature of the tumor microenvironment (TME), and the risk of systemic toxicity caused by overlapping chemotherapy and immunotherapy still severely limit clinical benefits, representing a core bottleneck urgently requiring breakthroughs in current TNBC treatment [[6], [7], [8]]. Notably, disordered iron metabolism [9,10] and high expression levels of the NLRP3 inflammasome [11] in TNBC cells provide a natural molecular basis for the synergistic induction of ferroptosis, pyroptosis, and immunotherapy [[12], [13], [14]]. However, tumor therapies that eliminate cancer cells via oxidative stress are often restricted by the aberrantly activated glutathione (GSH)/glutathione peroxidase 4 (GPX4) antioxidant axis in tumor cells [[15], [16], [17]]. The hyperactivation of this axis is a crucial mechanism underlying therapeutic resistance in tumors [18,19]. Therefore, the development of combinatorial therapeutic strategies integrating multiple modalities to break the dual dilemma of chemoresistance and immunosuppression has become a key direction for improving the therapeutic efficacy of TNBC. To bypass these defensive networks, targeting subcellular organelles—particularly the mitochondria—has emerged as a highly sophisticated frontier. Mitochondria are not only the metabolic powerhouses of the cell but also the central commands for cellular stress surveillance and endogenous danger signal storage. The massive reactive oxygen species (ROS) generated during organelle-targeted phototherapy can directly short-circuit mitochondrial bioenergetics, deplete the antioxidant capacity of the GSH/GPX4 axis, and lower the threshold of therapeutic damage [20]. Furthermore, direct disruption of mitochondrial structural integrity can prompt the leakage of mitochondrial DNA (mtDNA) into the cytoplasm, which acts as a potent endogenous "danger signal" capable of awakening the cytosolic DNA sensor cGAS and its adaptor STING-mediated signaling pathway to reverse immunosuppression [[21], [22], [23], [24], [25]]. Gemcitabine (GEM), a widely used clinical chemotherapeutic agent, exerts antitumor effects by interfering with nucleotide metabolism. However, the free 4′-amino group of GEM is prone to deamination and inactivation by cytidine deaminase (CDA), leading to reduced intratumoral drug concentration and compromised efficacy. Modification of its amino group has been proven an effective strategy to enhance pharmacological activity [[26], [27], [28], [29], [30]]. IR820, a classic phototherapeutic agent, functions as both a photothermal agent and a photosensitizer [31,32]. The chlorine atom in its molecular structure can serve as a carboxyl-introducing site, enabling further chemical modification [[33], [34], [35]]. Owing to its structural framework, IG displays the classic characteristics of a delocalized lipophilic cation (DLC), whereby the internally delocalized positive charge center is strongly driven by the substantial mitochondrial transmembrane potential gradient, ultimately leading to its enrichment at the mitochondria [[36], [37], [38]]. Metal-organic frameworks (MOFs), characterized by high specific surface area and structural tunability, enable high-efficiency drug loading and EPR effect-mediated tumor accumulation [39,40]. Iron-based MOFs can achieve pH- or GSH-responsive drug release by exploiting TME characteristics [[41], [42], [43]]. However, the simple doping and integration of multiple therapeutic agents without rational design can hardly achieve the synergistic effects of precise tumor killing and immune activation. To break through the clinical bottlenecks of therapeutic resistance and immunosuppressive microenvironment in TNBC, herein we report a spatiotemporally controlled mitochondrial interference strategy to orchestrate a robust cGAS–STING-mediated immune awakening. Rather than simply combining therapeutic agents, the engineered nanoplatform, IR820-GEM@MIL101 (IGM), achieves tumor-targeted accumulation via the EPR effect and selectively colonizes the mitochondrial matrix through electrostatic homing. Upon NIR irradiation, IGM acts as a localized "molecular detonator" within the mitochondria, igniting an explosive burst of ROS and regional hyperthermia. This catastrophic mitochondrial crisis not only triggers multi-channeled cell death subroutines (apoptosis, ferroptosis, and pyroptosis) to dismantle chemoresistance, but more importantly, forces the massive leakage of mitochondrial DNA (mtDNA) into the cytosol. This localized intervention initiates a powerful cascade that successfully premium-activates the cGAS–STING–IRF3 pathway, converting the immunologically "cold" TME into a highly receptive "hot" state. This work shifts the focus from superficial multi-drug packaging to precise organelle-targeted interference, providing a conceptual paradigm for light-regulated systemic anti-tumor immunity. (Fig. 1). Spatiotemporally regulated nanoplatform for synergistic induction of apoptosis/ferroptosis/pyroptosis and systemic immune activation in TNBC. (a) Schematic illustration of the IGM. The prodrug IG, conjugated via a photo-cleavable amide bond, is interacted with Fe3+ clusters in MIL-101(Fe), forming a dual acid/glutathione-responsive nanoplatform. (b) Mechanism of cellular cytotoxicity. Under acidic conditions, the IGM complex disassembles, releasing Fe3+ ions to prime ferroptosis while simultaneously liberating the IG prodrug for mitochondrial targeting. Upon 660 nm near-infrared light irradiation, three synergistic actions are triggered: (i) Light-mediated drug release: ROS-induced cleavage of the amide bond releases GEM, leading to DNA damage and p53-mediated apoptosis. (ii) In-situ mitochondrial ROS and hyperthermia inhibit the SLC7A11/GPX4 axis, exacerbating lipid peroxidation (LPO) and ferroptosis. (iii) Mitochondrial DNA activates the NLRP3 inflammasome/caspase-1 axis to induce pyroptosis and is concurrently recognized by cGAS, activating the cGAS-STING pathway. (c) Multipathway-induced in vivo immune activation. DAMPs (e.g., CRT, HMGB1, ATP, mtDNA) released during ferroptosis and pyroptosis promote dendritic cell maturation. This process, synergizing with cGAS-STING pathway activation, elicits a systemic anti-tumor immune response and generates an abscopal effect against distant tumors. Experimental section Materials All chemicals mentioned were purchased from Aladdin, Macklin, J&K Scientific, Energy Chemistry, and Thermo Fisher Scientific. Isoflurane for in vivo imaging was purchased from RWD Life Science. Reagents for cell experiments, including Fetal Bovine Serum (FBS), RPMI-1640 medium, 1% protease inhibitor cocktail, Triton X-100, Hoechst 33,342, Mito-Tracker Deep Red, Fe2+ RhoNox-6, primary antibody, secondary antibody, and flow antibody, were purchased from Beyotime Biotechnology, ZenBio, and Abcam. A Milli-Q system supplied ultrapure water (resistivity > 18.2 MΩ cm) for all cell-related experiments. No additional purification was performed on the analytical-grade reagents utilized in this work. Synthesis of IG Into a three-neck flask were added IR820 (0.802 g), 6-aminohexanoic acid (0.243 g), and DMF (30 mL). Under N2 gas, the reaction mixture was maintained at 85 °C. A solution of triethylamine in DMF was added dropwise slowly, and the temperature was maintained for 4 h. A distinct color change of the reaction mixture from green to blue was observed. Thin-layer chromatography (TLC) was applied to confirm when the reaction finished, which indicated the disappearance of the IR820 spot (eluent: ethyl acetate/methanol = 2:1). Following reaction termination, DMF was evaporated under reduced pressure, and the residue underwent three methanol solvent exchanges. The crude product was purified by dry-loading silica gel column chromatography (gradient elution: ethyl acetate/methanol = 40:1 to 2:1) to afford the intermediate IR820-COOH. The yield was 80.4%. 1H NMR (400 MHz, d6-DMSO) δ 8.16 (d, J = 8.6 Hz, 2H), 7.97 (dd, J = 8.7, 3.5 Hz, 4H), 7.74 (d, J = 13.4 Hz, 2H), 7.57 (dd, J = 11.7, 8.3 Hz, 4H), 7.39 (t, J = 7.5 Hz, 2H), 5.86 (d, J = 12.9 Hz, 2H), 4.09 (t, J = 7.1 Hz, 4H), 3.75 (t, J = 6.8 Hz, 2H), 2.63 – 2.52 (m, 8H), 2.25 (t, J = 7.4 Hz, 2H), 1.90 (s, 12H), 1.78 (pd, J = 10.2, 4.6 Hz, 14H), 1.59 (q, J = 7.6 Hz, 2H). HR-MS (ESI, negative mode, m/z): calcd for C52H62N3NaO8S2 [M − H]-: 942.3876, found: 942.5580. Into a three-necked flask were added IR820-COOH (0.550 g) and double-distilled water (30 mL). At room temperature, EDC and Sulfo-NHS were added to activate the mixture for 4 h. Subsequently, gemcitabine (0.378 g) and triethylamine (TEA, 0.565 g) were introduced. Stirring of the reaction mixture was carried out for 20 h at room temperature in dark. Reaction termination was confirmed by thin-layer chromatography (TLC), which indicated the disappearance of the IR820-COOH spot (eluent: ethyl acetate/methanol = 1:1). Following reaction termination, solvent was removed in vacuo. The residue was exchanged with methanol three times, and the crude product was further purified by dry-loaded silica gel column (gradient elution: ethyl acetate/methanol, 10:1 → 1:1) to afford the final product IG. 1H NMR (400 MHz, d6-DMSO) δ 8.39 (s, 1H), 8.13 (d, J = 9.9 Hz, 2H), 8.02 – 7.88 (m, 4H), 7.73 (d, J = 7.4 Hz, 2H), 7.57 (q, J = 9.3 Hz, 4H), 7.36 (dd, J = 13.9, 5.6 Hz, 3H), 6.11 (t, J = 8.2 Hz, 1H), 5.90 (d, J = 5.9 Hz, 1H), 5.81 (d, J = 12.9 Hz, 2H), 4.22 – 4.09 (m, 4H), 3.81 – 3.75 (m, 4H), 3.29 (s, 2H), 2.94 (s, 2H), 2.87 (s, 2H), 2.59 – 2.52 (m, 8H), 1.87 (d, J = 8.2 Hz, 12H), 1.82 – 1.65 (m, 16H). HR-MS (ESI, negative mode, m/z): calcd for C61H71F2N6NaO11S2 [M − H]-: 1187.4488, found: 1187.4406. Synthesis of IGM Into a three-necked flask were added iron(III) chloride hexahydrate (4 equiv.), 2-aminoterephthalic acid (3 equiv.), DMF, and ethanol. The mixture was dissolved by sonication and then refluxed at 60 °C for 8 h. The resulting solid was washed with DMF three times, followed by five cycles of centrifugation and solvent exchange with double-distilled water. The product was finally obtained by lyophilization to yield MIL-101(Fe). Into a three-necked flask were added MIL-101(Fe) and IG in equal mass ratios, along with a 20% methanol aqueous solution. A 24-h stirring process was conducted on the mixture at RT. The solid was then collected and subjected to five cycles of centrifugation and solvent exchange with double-distilled water, followed by lyophilization to afford the final product IGM. Determination of drug loading content and encapsulation performance for GEM and IG The standard curves for the ultraviolet (UV) absorption versus concentration of GEM and IG were established using UV-Vis spectrophotometry. MOF and IG were precisely weighed at mass ratios of 3:1, 2:1, 1:1, 1:2, and 1:3. The mixtures were then shaken on an orbital shaker in the dark for 12 h. Subsequently, the suspensions were spun down at 12,000 rpm for 10 min. The resulting precipitate was collected and freeze-dried to obtain the final product, IGM. The supernatant was collected, and the absorbance at 665 nm was measured using a UV-Vis spectrophotometer. The concentration of unloaded (free) IG was calculated based on the corresponding standard curve. This value was then used to calculate the drug loading (DL%) and encapsulation efficiency (EE%) according to the following formulas: Mass of loaded IG refers to the mass of IG successfully encapsulated. Mass of dried IGM nanoparticles is the mass of the freeze-dried nanoparticle product (IGM). Total mass of IG input is the initial total mass of IG used in the preparation. Drug release and photoresponsive performance test PBS dispersions of IGM (1 mg/mL) were prepared at pH 5.5 and 7.4, corresponding to tumor microenvironmental and physiological conditions, respectively. The samples were placed in a 37 °C shaker and oscillated in the dark. The concentration of IG in the supernatant was monitored at a wavelength of 665 nm using a UV-Vis spectrophotometer to calculate the cumulative release rate. In a separate experiment, IGM (150 μg/mL) was irradiated with a 660 nm laser (1 W/cm2). GEM content in the supernatant was spectrophotometrically determined at 268 nm to evaluate the cumulative drug release. Photothermal performance test Aqueous solutions of IGM at different concentrations (0, 100, 200, 400 μg/mL) were placed in 1.5 mL centrifuge tubes. An infrared thermal imaging camera was used to capture the real-time temperature variations of the solutions exposed to a 660 nm laser (1 W/cm2) for 10 min. Deionized water was employed as a blank control. The photothermal transduction efficiency (η) reaches to 40.4% according to the recorded heating-cooling curves. where η represents the efficiency of the energy conversion process (expressed as a percentage), m, c, ΔT, and Elight denote the liquid mass (kg), specific heat capacity (J/(kg·K)), temperature variation (K), and incident light energy (J), respectively. The input light energy can be calculated by multiplying the light intensity (W/m2) by the irradiated area (m2) and the irradiation time (s). The efficiency of the energy conversion process was determined by measuring the temperature change of the liquid when exposed to light, with the input light energy controlled appropriately based on the experimental setup. Assessment of reactive oxygen species (ROS) generation capability 1,3-Diphenylisobenzofuran (DPBF) was used as the ROS probe. DPBF (20 μM) was mixed with different samples (PBS, IG, IGM, IGM + H2O2) in PBS. The mixtures were irradiated with a 660 nm laser (1 W/cm2) for varying durations (0-10 min). The ROS generation capability of each group was evaluated by monitoring the attenuation of the characteristic absorption peak of DPBF at 410 nm. Glutathione (GSH) depletion capability test The response of IGM to GSH was measured with 5,5′-dithiobis(2-nitrobenzoic acid) (DTNB). Different concentrations of IGM were incubated with a fixed concentration of GSH (2 mM) in PBS (pH 7.4) at 37 °C for 10 min. Subsequently, the absorbance of the mixture at 412 nm was measured. The degree of absorbance reduction reflected the GSH depletion capability of IGM. Cytotoxicity assay (CCK-8 method) RPMI-1640 medium (Pricella) containing 10% fetal bovine serum (FBS, Gibco) and 2 mM glutamine was used to culture 4T1 cells. Incubation conditions were set at 37 °C with 5% CO2 and 95% air. 4T1 cells (5 × 103/well) were seeded in 96-well plates and incubated overnight for adherence, followed by replacement of the medium with serum-free formulations containing varying sample concentrations (GEM, IG, IGM, etc., calculated based on the concentration of GEM or equivalent drug). The cells were incubated for 6 h. For the laser irradiation group, the medium was aspirated, and the cells were gently washed once with PBS. Fresh medium was then added, and the cells were irradiated with a 660 nm laser (1.5 W/cm2) for 5 min. Following an additional 18-h incubation, 10 μL of CCK-8 reagent was dispensed into each well and the plates were incubated for 1 h. The optical density at 450 nm was then read on a microplate reader to determine cell viability. Cellular internalization and subcellular localization 4T1 cells were seeded in confocal dishes and incubated afterwards with FITC-labeled IGM (equivalent IG concentration: 10 μg/mL) for 2, 4, 6, and 8 h, respectively. Following incubation, the cells underwent three consecutive washes with PBS. Mitochondria were stained with Mito-Tracker Deep Red FM (50 nM), and nuclear staining was performed with Hoechst 33,342 (5 μg/mL) for 30 min. Observation and documentation of fluorescence images were performed via a Leica inverted fluorescence microscope. The Pearson's correlation coefficient (Pearson's R) between the FITC fluorescence signal and the Mito-Tracker Deep Red FM fluorescence signal was calculated using Image J software to evaluate the mitochondrial enrichment capability of IGM. Evaluation of cellular mitochondrial membrane potential (MMP) The JC-1 fluorescent probe is used for detection. After different treatments, cells are subjected to JC-1 staining at 37 °C for a duration of 30 min. Following PBS washing, observation is performed using a fluorescence microscope. JC-1 forms red-fluorescent aggregates in normal cells with high mitochondrial membrane potential. Reduced potential converts JC-1 into green-fluorescent monomers. Mitochondrial membrane potential variations are evaluated via the red/green fluorescence intensity ratio. Cellular ferrous ion (Fe2+) detection Fluorescence Microscopy Observation: After drug treatment, the supernatant was discarded, and the cells were washed three times with serum-free medium. The cells were then incubated with 1 μM RhoNox-6 working solution at 37 °C in the dark for 30 min. Following incubation, the cells were directly observed under a fluorescence microscope to assess red fluorescence intensity without any washing step. Flow Cytometry Quantitative Analysis: After drug treatment, cells were harvested and centrifuged at 1500 rpm for 3 min. The cell pellet was washed with serum-free medium. After the supernatant was discarded, the cells were resuspended in 300 μL of serum-free medium containing 1 μM FerroOrange and incubated at 37 °C in the dark for 15 min. The cells were then analyzed using a flow cytometer with the PE channel. The mean fluorescence intensity (MFI) and the percentage of Fe2+-positive cells were determined to quantitatively evaluate the intracellular Fe2+ levels. Apoptosis detection (flow cytometry) An Annexin V-FITC/PI double staining kit is used. Cells subjected to different treatments are collected, washed twice with pre-cooled PBS, and diluted in 1× Binding Buffer for resuspension. Then, 5 μL of Annexin V-FITC/PI dual-staining solution was applied and incubated in darkness for 15 min. Analysis is subsequently performed using a flow cytometer (BD FACSCanto II). GSH/GSSG ratio determination GSH and GSSG detection kits are used. Cells are collected and lysed. Following the kit instructions, the absorbance at 412 nm was determined using a microplate reader to obtain the contents of total GSH and GSSG, as well as their ratio. Lipid peroxidation (LPO) assay The C11-BODIPY 581/591 probe is used. After treatment, a 5 μM working solution of the probe was added to cells, followed by 30 min of incubation at 37 °C away from light. Following PBS washing, fluorescence signals are detected using a fluorescence microscope or flow cytometer (oxidized state emits green fluorescence, reduced state emits red fluorescence). Malondialdehyde (MDA) content determination An MDA detection kit is used. Cells are collected and lysed. According to the kit instructions, after reaction between the lysate and thiobarbituric acid (TBA), 532 nm absorbance was read on a microplate reader. Lactate dehydrogenase (LDH) release An LDH detection kit is used. Cell culture supernatant is collected, mixed with the reaction substrate according to the kit instructions, incubated, and then absorbance at 490 nm is measured. Inflammatory cytokine IL-1β and IL-18 detection Mouse IL-1β and IL-18 ELISA kits are used. Cell culture supernatant is collected, and the steps are performed according to the kit instructions, followed by measurement of absorbance at 450 nm. Detection of immunogenic cell death (ICD) markers (1)Exposure of Cell Surface Calreticulin (CRT): Perform immunofluorescence staining using an anti-CRT antibody. After being fixed, permeabilized, and blocked, the cells were exposed to the primary antibody for an overnight incubation, after which they were incubated with a fluorescently labeled secondary antibody, and observed under a fluorescence microscope. Exposure of Cell Surface Calreticulin (CRT): Perform immunofluorescence staining using an anti-CRT antibody. After being fixed, permeabilized, and blocked, the cells were exposed to the primary antibody for an overnight incubation, after which they were incubated with a fluorescently labeled secondary antibody, and observed under a fluorescence microscope. (2)Efflux of Cytokine (HMGB1): Perform immunofluorescence staining using an anti-HMGB1 antibody. After fixation, permeabilization, and blocking, cells are treated with the primary antibody and incubated overnight, subsequently exposed to a fluorophore-conjugated secondary antibody, and observed under a fluorescence microscope. Efflux of Cytokine (HMGB1): Perform immunofluorescence staining using an anti-HMGB1 antibody. After fixation, permeabilization, and blocking, cells are treated with the primary antibody and incubated overnight, subsequently exposed to a fluorophore-conjugated secondary antibody, and observed under a fluorescence microscope. (3)Release of Extracellular HMGB1 and ATP: Collect cell culture supernatants and perform quantitative detection using an HMGB1-ELISA kit and an ATP detection kit, respectively. Release of Extracellular HMGB1 and ATP: Collect cell culture supernatants and perform quantitative detection using an HMGB1-ELISA kit and an ATP detection kit, respectively. Western blot analysis Cells under various treatment conditions were pooled and homogenized in RIPA buffer (with protease and phosphatase inhibitors) on ice for 30 min. After centrifugation, collect the supernatant and determine the protein concentration. Equal amounts of protein lysates were resolved by SDS-PAGE and subsequently electrotransferred onto PVDF membranes. After blocking with 5% non-fat milk for 1 h, the membranes were probed with the corresponding primary antibodies (e.g., GPX4, SLC7A11, Cle-Caspase-3, BAX, BCL-2, Caspase-1 p20, GSDMD-N, Cytochrome C, p-TBK1, p-IRF3, etc.) at 4 °C overnight. Following TBST washing, samples were subsequently reacted with HRP-linked secondary antibody for a 1-h period. Develop the signal using ECL chemiluminescence reagent and capture images with a chemiluminescence imaging system. Use β-actin/GAPDH as internal controls and perform semi-quantitative analysis of band intensity using ImageJ software. In vitro validation of DC maturation Take 6-8 week-old BALB/c mice, euthanize them by cervical dislocation, and isolate femurs and tibias under sterile conditions. Flush the bone marrow cavity using complete medium (e.g., RPMI 1640 containing 10% fetal bovine serum) to collect the cell suspension. The bone marrow cells were passed through a 70 μm cell strainer and pelleted by centrifugation to yield a single-cell suspension. Resuspend the cells in BMDC differentiation medium (with GM-CSF and IL-4 concentrations at 20 ng/mL and 10 ng/mL, respectively). Adjust cellular concentration to 5 × 105 cells per milliliter. By day 7 of culture, a large number of immature DCs can be harvested.Seed mouse breast cancer 4T1 cells at a density of 5 × 105 cells/well in the upper chamber of a Transwell insert. After adherence, treat with drug groups, while simultaneously seeding 1 × 106 immature BMDCs/well in the lower chamber. Continue co-culture for 24 h. After co-culture, collect BMDCs from the lower chamber. Stain and quantitatively analyze their maturation markers using flow cytometry. Animal experiment Animal Experiment Ethics Number:Rendongke Batch No. [2025] No. 478. And all of 4T1 xenograft tumor-bearing BALB/c mice were anesthetized by inhalation of isoflurane before injection. Evaluation of overall therapeutic efficacy via unilateral tumor-bearing mouse model combined with intravenous injection Female BALB/c mice (18–20 g, 5 weeks of age) were raised under SPF conditions following animal ethical regulations. 4T1 cells (1 × 106 cells/mouse) were resuspended in 100 μL Matrigel and injected subcutaneously into the left back. The tumor model was established successfully when the tumor volume reached 100 mm3. All mice were randomly allocated to seven groups (n = 5 for each group): NC, MOF, GEM, IG, IG + NIR, IGM, and IGM + NIR. Drugs were administered intravenously every 3 days (days 0, 3, 6) at 5 mg/kg. Six hours after injection, NIR groups were anesthetized and irradiated with a 660 nm laser for 2 min. Measurements of body weight and tumor volume were conducted every 3 days. After three administrations, monitoring continued until day 17, when mice were humanely killed. Tumors were excised, gravimetrically measured, and imaged. The tumor specimens were subjected to histopathological analysis. In vivo biodistribution was tracked by small animal live imaging at the first administration. IGM@Cy5.5 was prepared by incubating Cy5.5 with IGM at 37 °C with constant shaking for 12 h, followed by centrifugation (16,000 r/min, 10 min) to remove free Cy5.5 and washing with normal saline. Compared with free Cy5.5, in vivo imaging was performed at 1, 2, 4, 8, 12, 24, 36, 48, and 96 h after intravenous injection. Tumor accumulation and retention of IGM were evaluated by analyzing and quantifying fluorescence intensity at the tumor site. Verification of immune activation effect via bilateral tumor-bearing mouse model Female BALB/c mice at 5 weeks of age (18–20 g) were housed in an SPF environment in compliance with animal ethics. 1 × 106 4T1 cells were resuspended in 100 μL Matrigel and subcutaneously injected into the left dorsal region of each mouse. Once the volume of the left tumor reached 80 mm3, 1 × 106 4T1 cells were inoculated on the right side. The model was successfully established when the right tumor volume also reached 80 mm3. All mice were randomly allocated to five groups (n = 5 for each group): NC, NC + NIR, GEM, IGM, and IGM + NIR. Peritumoral injections were given into the left tumor every 4 days (days 0, 4, 8, 12) at 5 mg/kg. Six hours post-injection, NIR groups received 660 nm laser irradiation on the left tumor for 2 min, while the right tumor remained untreated. Body weight and tumor dimensions were monitored at 2-day intervals. Upon completion of the 16-day period, the mice were euthanized, and the tumors and spleens were excised. Flow cytometry was used to analyze the expression levels of CD4+ T cells, CD8+ T cells in tumor-infiltrating lymphocytes (TILs) and costimulatory molecules (CD80/CD86) on dendritic cells (DCs). Meanwhile, the levels of cytokines including IFN-γ and TNF-α in tumor homogenates were determined using ELISA kits. Biosafety assessment During the entire treatment course, mice were weighed periodically. The heart, liver, spleen, lungs and kidneys were excised post-treatment for hematoxylin and eosin (H&E) staining, so as to analyze histopathological variations. Statistical analysis Results are reported as mean ± SD from at least three independent experiments. Statistical analyses were performed using GraphPad Prism 9.0: Student's t-test for pairwise comparisons and one-way ANOVA for multiple-group comparisons. Significance was defined as *P < 0.05, **P < 0.01, and ***P < 0.001. Results and discussion Fabrication and characterization of the iron-based nanoplatform IGM The photoresponsive agent IR820 was first coupled with 6-aminocaproic acid for carboxyl group modification, yielding the intermediate IR820-COOH (Fig. 2a). A distinct color transition from green to blue was observed in the reaction solution. Subsequently, IR820-COOH was conjugated with the chemotherapeutic drug gemcitabine (GEM) via an amidation reaction to form the prodrug IR820-GEM (IG). The reaction process was monitored by ultraviolet–visible (UV-Vis) absorption spectroscopy (Fig. 2b). After substitution of the meso-chlorine atom by the secondary amine group in 6-aminocaproic acid, a strong electron-donating moiety, the conjugated chain was shortened and the HOMO–LUMO energy gap (ΔE) increased [44], leading to a blue-shift of the absorption peak to 660 nm. Following amidation with gemcitabine, the absorption peak red-shifted to 665 nm. Purification of the product was carried out via column chromatography with a yield of approximately 64.2%. Structural characterization by 1H NMR and ESI-MS confirmed the successful synthesis of the target prodrug IG (Fig. S1). Fabrication and characterization of IGM. (a) Synthetic route of the prodrug IG; i = 6-aminocaproic acid, ii = GEM; (b) UV-Vis absorption spectra of IR820, IR820-COOH, and IR820-GEM (IG); (c, d) SEM image and hydrated particle size of the MIL-101(Fe) carrier (scale bar = 200 nm); (e, f) SEM image and hydrated particle size of IGM (scale bar = 200 nm); (g) TEM image and elemental mapping of IGM; (h) Drug loading content (DLC) and encapsulation efficiency (EE) of IGM at different IG/MIL-101 mass ratios; (i) Zeta potentials of IGM and its components; (j) XRD patterns of IGM and related materials. MIL-101(Fe) was synthesized using the hydrothermal approach. After solvent exchange, it was mixed with the prodrug IG and reacted for 24 h. The final nanocomposite IR820-GEM@MIL-101 (IGM) was obtained after washing and drying. SEM images showed that IGM retained the octahedral morphology of pristine MIL-101 (Fig. 2c–e), while exhibiting significantly increased surface roughness (Fig. S2). Dynamic light scattering (DLS) examination confirmed that the hydrated particle size of IGM increased from 120.5 ± 1.8 nm to 220.0 ± 9.5 nm (PDI < 0.05) (Fig. 2d–f). Elemental mapping of IGM showed uniform distribution of Fe, S, and F on the nanoparticle surface (S from IR820, F from GEM), verifying successful integration (Fig. 2g). Systematic optimization of the IG/MIL-101 mass ratio from 3:1 to 1:3 demonstrated that the mass ratio of 1:1 achieved the highest encapsulation efficiency (89.52 ± 2.1%) and drug loading content (47.23 ± 1.8%) (Fig. 2h) [45]. The zeta potential of IGM was −22.5 ± 1.8 mV (Fig. 2i), ensuring good colloidal stability. XRD patterns (Fig. 2j) showed that the characteristic diffraction peaks at 2θ = 9.6° and 10.3° were preserved after IG loading, indicating that the crystalline structure of MIL-101 remained intact, albeit with slightly reduced peak intensity [46,47]. Physicochemical properties of IGM As a pH-responsive nanocarrier, MIL-101(Fe) undergoes specific structural dissociation in the acidic tumor microenvironment (pH 5.5), enabling intelligent controlled drug release. This behavior arises mainly from protonation of coordination bonds between Fe3+ and organic ligands under acidic conditions, weakening binding interactions and ultimately triggering collapse of the MOF framework [42]. In vitro release experiments verified this property. In acidic PBS (pH 5.5) simulating the tumor microenvironment, IGM rapidly released the prodrug IG (Fig. 3a), with a cumulative release of 63.9% within the first 6 h and 76.16% at 48 h. In contrast, in neutral PBS (pH 7.4) mimicking normal physiological conditions, the corresponding release values were only 19.0% and 29.22%, respectively. This marked difference with release under acidic conditions approximately 2.6-fold higher than under neutral conditions fully confirmed the excellent tumor microenvironment-responsive release behavior of IGM [48]. Physicochemical properties of IGM. (a) In vitro IG release profiles of IGM in PBS at different pH values (n = 3). (b) UV-Vis absorption spectra of IG solution at various time intervals under 660 nm laser irradiation (0–120 s). (c) Photolysis curve of IG under 660 nm laser irradiation (n = 3). (d) Temperature changes of water, MOF, IG, and IGM under 660 nm laser irradiation (1.0 W cm−2) for 0–5 min (n = 3). (e) Infrared thermal images of IGM at different concentrations and irradiation durations. (f) Photothermal conversion efficiency of IGM (n = 3). (g) Absorbance changes of DPBF at 417 nm for DPBF, DPBF + MOF, and DPBF + IGM under laser irradiation (n = 3). (h) Absorbance changes of DPBF at 417 nm for the same groups in the dark (n = 3). (i) UV-Vis absorption spectra of DTNB solution after 10 min incubation of GSH (2 mM) with varying concentrations of IGM. Upon 660 nm laser irradiation, the absorption peak of IG gradually decreased while that of GEM increased (Fig. 3b), confirming light-triggered cleavage of the amide bond and release of GEM. The photolysis half-life of IG under 660 nm laser irradiation was approximately 64.40 s (Fig. 3c), whereas no release occurred in the dark (Fig. S4), indicating light-controlled release of the chemotherapeutic agent from the prodrug. Simultaneously, the structural integrity and stability of the GEM released from the system were verified by HPLC. The results showed that the retention time of GEM gradually released from the system after 660 nm laser irradiation (2.642 min) was in excellent agreement with that of the standard (2.632 min), demonstrating that the 660 nm laser irradiation did not compromise the chemical structure of GEM and the released drug fully maintained its molecular integrity and stability (Fig. S5). This effect was attributed to reactive oxygen species (ROS)-mediated cleavage of the amide linkage between IR820 and GEM. For photothermal performance, the temperature-elevating capacity of IGM was evaluated in vitro. IGM, IG, MOF, and pure water were exposed to 660 nm laser irradiation (1 W/cm2) for 5 min. As shown in Fig. 3d, the temperatures of the IG and IGM groups sharply increased to 60.2 °C and 73.9 °C, respectively. In contrast, the MOF group exhibited only an 11.2 °C increase, and water showed a negligible rise of 2.2 °C. Temperature elevation of IGM aqueous dispersions at concentrations from 0 to 400 μg/mL was further recorded under identical laser irradiation for 5 min, with infrared thermal imaging providing intuitive visualization (Fig. 3e). The photothermal effect exhibited obvious concentration dependence. IGM (200 μg/mL) induced a temperature increase of 27 °C within 120 s, while water showed almost no change. The photothermal conversion efficiency of IGM was calculated to be η = 40.4% (Fig. 3f). Moreover, IGM maintained stable heating–cooling cycles over three repeated irradiations, demonstrating excellent photostability (Fig. S6). For photodynamic performance, ROS generation was measured using the probe 1,3-diphenylisobenzofuran (DPBF). Under continuous laser irradiation (Fig. 3g), IGM and IG exhibited comparable ROS generation in aqueous solution. When hydrogen peroxide (4 μM) was used as the substrate, IGM generated significantly more ROS than IG. In the dark (Fig. 3h), monitoring of absorbance at 417 nm revealed that MOF and IGM still produced ROS in the presence of H2O2, owing to the catalase-like activity of iron-based MOFs, which synergistically enhanced the photodynamic performance of IGM [49]. ROS production by IGM at concentrations from 0 to 400 μg/mL after 10 min of laser irradiation showed concentration-dependent behavior (Fig. S7). The response of IGM to GSH was examined using 5,5′-dithiobis(2-nitrobenzoic acid) (DTNB) by monitoring absorbance changes at 412 nm. After incubation with varying concentrations of IGM for 10 min, the absorbance at 412 nm decreased in a concentration-dependent manner (Fig. 3i), indicating that iron ions in IGM consumed highly expressed GSH in tumors and were reduced to Fe2+ to drive the Fenton reaction. In vitro antitumor efficacy of IGM Efficient cellular internalization is a prerequisite for IGM to exert cytotoxicity. Cellular uptake experiments were performed using mouse breast cancer 4T1 cells incubated with FITC-labeled IGM for 2, 4, 6, and 8 h (Fig. 4a). Fluorescence intensity gradually increased, peaked at 6 h, and stabilized at 8 h, indicating that cellular uptake of IGM reached a maximum at 6 h (Fig. 4b). Mitochondrial co-localization assays performed at 6 h post-administration showed high correlation between the red mitochondrial channel and the green IGM channel (Pearson's r = 0.837) (Fig. 4c). IGM exhibits a net negative Zeta potential in the aqueous phase, enabling the establishment of a strong electrostatic repulsion barrier that prevents nonspecific interception by non-target cellular components [50,51]. After cellular internalization, IGM undergoes responsive degradation and disassembly to release IG. Owing to its structural framework, IG displays the classic characteristics of a delocalized lipophilic cation (DLC), whereby the internally delocalized positive charge center is strongly driven by the substantial mitochondrial transmembrane potential gradient, ultimately leading to its enrichment at the mitochondria [52,53]. In vitro antitumor effects of IGM. (a) Fluorescence microscopy images of 4T1 cells incubated with FITC-labeled IGM at different time points (scale bar: 25 μm). (b) Quantification of green fluorescence intensity in (a). (c) Fluorescence co-localization of IGM-FITC and mitochondria in 4T1 cells after 6 h incubation (scale bar: 25 μm). (d) GSH/GSSG ratios in different treatment groups. (e) Intracellular ATP levels after various treatments. (f) Intracellular ROS levels visualized by DCFH-DA green fluorescence in PBS, MOF, GEM, IGM, and IGM + NIR groups. (g) Quantification of green fluorescence intensity in (f). (h) Flow cytometric analysis of the percentage of ROS-positive cells. (i) Quantitative analysis of mean fluorescence intensity. (j) JC-1 staining fluorescence images of cells after different treatments. (k) Red/green fluorescence intensity ratio from JC-1 staining. (l) Viability of 4T1 cells exposed to varying concentrations of GEM, IG, and IG + NIR. (m) Viability of 4T1 cells exposed to varying concentrations of MOF, GEM, IGM, and IGM + NIR. (n) Effects of ferroptosis, apoptosis, and pyroptosis inhibitors on IGM + NIR-mediated cytotoxicity. (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.) The GSH/GSSG ratio is a gold standard for cellular redox homeostasis, directly reflecting antioxidant capacity and oxidative stress. Under physiological conditions, the GSH/GSSG ratio is approximately 10:1, maintaining a strongly reductive environment that protects DNA and lipids from oxidative damage while sustaining GPX4 activity and contributing to drug resistance [54]. The GSH/GSSG ratio in the IGM + NIR group dropped to 1.5:1 compared with the control group (Fig. 4d), indicating severe oxidative stress, disrupted cellular homeostasis, and collapse of the antioxidant system due to in situ mitochondrial ROS generation. Mitochondrial damage impaired ATP production, which is essential for tumor cell proliferation and survival. Intracellular ATP levels in the IGM + NIR group decreased by 72.33% compared with the PBS group (Fig. 4e). Intracellular ROS levels were visualized by inverted fluorescence microscopy (Fig. 4f) and quantified (Fig. 4g). The ROS fluorescence intensity in the IGM + NIR group was 4.78-fold and 2.99-fold higher than in the PBS and single-agent groups, respectively. Flow cytometry analysis revealed that, compared with the GEM group, the IGM + NIR group exhibited the most pronounced rightward shift in fluorescence signal. The proportion of ROS-positive cells in the IGM + NIR group reached 92.5%, and the mean fluorescence intensity was increased by 2.41-fold relative to the GEM group (Fig. 4h and i), confirming that IGM + NIR significantly boosted intracellular ROS levels and disrupted cellular homeostasis. Mitochondrial membrane potential (ΔΨm) [55] was assessed using JC-1 staining. Depolarization led to the appearance of green fluorescence (Fig. 4j and k). The IGM + NIR group displayed intense green fluorescence with almost complete loss of red fluorescence, indicating severely reduced ΔΨm and damaged mitochondrial matrix integrity. These results confirmed that IGM + NIR disrupts the cellular antioxidant system and impairs mitochondrial function, leading to cell death. Cell Counting Kit-8 (CCK-8) was used to assess cytotoxicity following 24-h treatment. IG exhibited lower cytotoxicity than free GEM (Fig. 4l). Upon laser irradiation, the amide bond in IG cleaved to release GEM, enabling synergistic chemotherapy and phototherapy with enhanced killing efficacy. Among PBS, MOF, GEM, IGM, and IGM + NIR groups (Fig. 4m), IGM + NIR showed superior inhibition. At a low drug concentration (1.5 μg/mL), the inhibition rate of IGM + NIR (67.39%) was 1.47-fold higher than that of GEM (45.73%), suggesting the involvement of additional cell death pathways beyond chemotherapy. To identify the death mechanisms, cells were co-treated with specific inhibitors of apoptosis, pyroptosis, and ferroptosis. As shown in Fig. 4n, IGM + NIR triggered all three death modes. MCC950 [56], an NLRP3 inhibitor, confirmed that IGM + NIR induced pyroptosis mainly through the canonical caspase1/GSDMD pathway. Mechanistic validation of antitumor activity in vitro The three cell death pathways were systematically verified. A schematic illustration of the killing mechanism is shown in Fig. 5a. Western blotting for apoptosis-related proteins (Fig. 5b) upregulated pro-apoptotic markers including BAX, cleaved-caspase-3 and cytochrome C, together with decreased BCL-2 expression, suggested the initiation of the mitochondrial intrinsic apoptosis pathway. Flow cytometric apoptosis analysis (Fig. 5c and d) showed that at 2 μM, GEM induced moderate apoptosis (12.38% early + 7.36% late), while IGM alone induced less apoptosis (7.2% + 7.9%), indicating sustained GEM release. In contrast, IGM + NIR induced the highest apoptosis rate (26.1% + 22.17%), owing to ROS burst and ferroptosis-mediated augmentation. For ferroptosis, intracellular Fe2+ was visualized using a fluorescent probe (red fluorescence; Fig. 5e and f). Flow cytometry analysis revealed that, compared with the GEM group, the IGM + NIR group exhibited the most pronounced rightward shift in fluorescence signal. The proportion of Fe2+-positive cells in the IGM + NIR group reached. Mechanistic validation of IGM-mediated antitumor activity in vitro. (a) Schematic illustration of IGM + NIR-induced apoptosis, ferroptosis, and pyroptosis via ROS, hyperthermia, Fe3+, and GEM release. (b) Western blot analysis of apoptosis-related proteins. (c) Flow cytometric apoptosis plots (Annexin V-FITC/PI). (d) Quantification of early and late apoptotic cells. (e) Intracellular Fe2+ visualized by RhoNox-6 red fluorescence. (f) Quantification of Fe2+ fluorescence intensity. (g) Flow cytometric analysis of the percentage of Fe2+-positive cells. (h) Quantitative analysis of mean fluorescence intensity. (i) Western blot detection of proteins implicated in ferroptosis. (j, k) Quantitative flow cytometric assessment of intracellular LPO. (l) MDA content measured in 4T1 cells following different treatment conditions. (m) Western blot analysis of pyroptosis-related proteins. (n) Extracellular LDH levels. (o) Extracellular IL-18 levels. (p) Extracellular IL-1β levels. TEM images of 4T1 cells after IGM + NIR treatment: (q) Pyroptotic bodies (↑) and chromatin condensation (○). (r) Apoptotic bodies (○) and membrane perforation (↑). (s) Pyroptotic bodies (○), increased mitochondrial membrane density, and disorganized cristae (↑). (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.) 89.4%, and the mean fluorescence intensity was increased by 3.04-fold relative to the GEM group (Fig. 5g and h). The IGM + NIR group exhibited the highest Fe2+ conversion, providing sufficient substrate for the Fenton reaction and lipid peroxidation. Western blotting (Fig. 5i) showed that DNA damage activated p53, transcriptionally repressed SLC7A11, inhibited cystine uptake, reduced GSH synthesis, and inactivated GPX4 [57], [58]. Thus, IGM + NIR inactivated the GSH/GPX4 antioxidant axis by suppressing the System Xc-system. Flow cytometric quantification of lipid peroxides (LPO) showed a 2.23-fold increase in the IGM + NIR group compared with the control (Fig. 5j and k). Malondialdehyde (MDA), a marker of lipid peroxidation, was increased by 3.71-fold (Fig. 5l). These results confirmed that IGM + NIR synergistically induces ferroptosis via ROS overproduction, System Xc-inhibition, and Fenton chemistry. Western blotting for the canonical pyroptotic pathway (caspase-1/GSDMD) (Fig. 5m) showed that IGM + NIR significantly upregulated the active fragment of caspase-1 (P20) by 2.18-fold and N-GSDMD by 2.59-fold compared with IGM alone, providing molecular evidence that laser irradiation activates pyroptosis. Pyroptosis-associated membrane damage and inflammatory factor release were verified by measuring LDH, IL-1β, and IL-18 in cell supernatants. LDH release increased by 214% compared with the PBS group (Fig. 5n), indicating severe membrane disruption. IL-1β and IL-18 levels increased by 117.08 ± 3.17% and 136.98 ± 2.71%, respectively (Fig. 5o and p). TEM imaging directly visualized pyroptotic bodies, chromatin condensation, apoptotic bodies, membrane pores, swollen mitochondria, and disorganized cristae accompanied by mtDNA release (Fig. 5q–s). Collectively, IGM + NIR enables light-controlled synergistic induction of apoptosis, ferroptosis, and pyroptosis. Light-triggered ICD and cGAS-STING pathway activation by IGM Owing to its high invasiveness and propensity for early metastasis, TNBC poses a formidable clinical challenge. While local therapies can effectively control the primary tumor, they often fail to eradicate distant metastatic lesions. Immunotherapy, which activates systemic T-cell responses, holds great promise for synergizing with local treatments to overcome this bottleneck in TNBC management. Our experimental results demonstrated that, in contrast to the PBS and material-only groups, IGM, upon laser irradiation, efficiently induces immunogenic cell death modalities, namely pyroptosis and ferroptosis, while disrupting the homeostatic regulation of tumor cells. Therefore, we hypothesized that laser-mediated modulation of IGM might enable controllable immune activation, thereby circumventing the limitations of traditional immunotherapy, such as systemic toxicity. First, we validated the capacity of IGM + NIR to induce immunogenic cell death. IGM + NIR generates reactive oxygen species (ROS) and heat in situ within mitochondria, leading to mitochondrial damage. This damage subsequently triggers the release of mitochondrial DNA (mtDNA) into the cytoplasm, thereby activating the cGAS-STING pathway. To visualize this process, we used. PicoGreen a green fluorescent dye, to label double-stranded DNA (dsDNA), and performed co-localization fluorescence imaging with red-labeled mitochondria (Fig. 6a). Pearson's correlation analysis [59] revealed the most distinct difference in subcellular localization in the IGM + NIR group (Fig. 6b), indicating the leakage of a portion of mtDNA from mitochondria [60]. Subsequently, immunofluorescence was used to localize intracellular cGAS (red) and dsDNA (PicoGreen). Fluorescence images and Pearson's correlation analysis demonstrated a strong correlation between cGAS and dsDNA in the IGM + NIR group (Fig. 6c and d). These results confirmed that IGM exhibits significant differences in mtDNA leakage and cGAS binding depending on whether laser irradiation was applied [61]. Concurrently, we verified the phosphorylation levels of downstream proteins in the cGAS-STING pathway via Western blot analysis. The results showed that the phosphorylation levels of p-TBK1 and p-IRF3 in the IGM + NIR group were significantly upregulated by 1.75-fold and 1.51-fold, respectively, compared with the IGM group (Fig. 6e). Collectively, these findings indicate that the material alone has limited effects on DAMPs release and cGAS-STING pathway activation, whereas laser irradiation substantially enhances these effects, suggesting that IGM holds great potential for light-controlled activation of ICD and antitumor immunity. A schematic depiction of the mechanism through which IGM + NIR triggers ICD and facilitates dendritic cells (DCs) maturation is shown in Fig. 6f. Following that, the secretion of classic damage-associated molecular patterns (DAMPs), including CRT, HMGB1, and ATP, was assessed. Quantitative analysis using commercial kits revealed that the ATP concentration in the cell supernatant of the IGM + NIR group was 217.8% higher than that of the IGM group (Fig. 6g). Immunofluorescence assays clearly observed the prominent translocation of CRT to the cell membrane in the IGM + NIR group, and quantitative fluorescence analysis showed significantly higher intensity compared with the IGM group (Fig. 6h and i). Meanwhile, in the IGM + NIR group, HMGB1 was observed to translocate from the nucleus to the cytoplasm and eventually be secreted extracellularly, which was manifested as a marked reduction in fluorescence signals in the nuclear region. In contrast, fluorescence signals in the blank control group were highly concentrated within the nucleus (Fig. 6j). ELISA quantification of HMGB1 in the cell supernatant demonstrated that its level in the IGM + NIR group was 138.7% higher than that in the IGM group (Fig. 6k). These results confirm that near-infrared (NIR) irradiation effectively triggers IGM-mediated immunogenic cell death (ICD). The synergistic release of these DAMPs collectively forms a comprehensive "danger signal network," laying a molecular foundation for the subsequent activation of innate and adaptive antitumor immune responses. Light-Controlled Activation of ICD and the cGAS-STING Pathway by IGM (a) Immunofluorescence co-localization images of mitochondria (red) and double-stranded DNA (dsDNA, stained by PicoGreen, green) in cells under different treatments. (b) Pearson's correlation analysis for the co-localization of mitochondria and dsDNA. (c) Immunofluorescence co-localization images of cGAS (red) and dsDNA (PicoGreen, green) in cells under different treatments. (d) Pearson's correlation analysis for the co-localization of cGAS and dsDNA. (e) WB evaluation of critical proteins in the cGAS-STING pathway across all treatment groups. (f) Schematic diagram illustrating the mechanism of IGM + NIR-induced dendritic cell maturation. (g) Detection results of ATP release in 4T1 cells from each treatment group. (h) Fluorescence images of CRT staining for each treatment group. (i) Quantitative comparison of CRT (green) fluorescence intensity as shown in Fig. h. (j) Fluorescence images of HMGB1 staining for each treatment group. (k) Quantitative comparison of HMGB1 (green) fluorescence intensity as shown in Fig. j. (l) Flow cytometric sorting plots of dendritic cells from each treatment group. (m) Flow cytometric analysis of mature dendritic cells across all treatment groups. (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.) We selected mouse bone marrow-derived dendritic cells (DCs) to co-culture in vitro with 4T1 cells subjected to interventions from different experimental groups. The expression of DC co-stimulatory molecules (CD80/CD86) was detected via flow cytometry to validate the ability of IGM to promote DC maturation [62]. As shown in Fig. 6l and m, compared to the IGM group, the IGM + NIR group exhibited a significant increase in the CD80/CD86 double-positive ratio (by 119.87%). This demonstrates that the presence or absence of laser irradiation significantly influences the capacity of IGM to promote DC maturation. Therefore, the material possesses the ability for light-controlled immune activation, along with the potential to circumvent the pro-tumor risks associated with sustained immune activation and T cell exhaustion. We performed in vitro co-culture experiments using mouse bone marrow-derived dendritic cells (DCs) and 4T1 cells treated with different experimental groups. The expression of DC co-stimulatory markers (CD80/CD86) was measured by flow cytometry, confirming that IGM promotes dendritic cell maturation [51]. The proportion of CD80/CD86 double-positive cells in the IGM + NIR group exhibited a 119.87% elevation relative to the IGM group. This confirms that laser irradiation significantly modulates the capacity of IGM to promote DC maturation. Thus, the material enables laser-regulated immune activation and holds the potential to avoid cancer-promoting risks and T-cell exhaustion caused by sustained immune activation. In vivo antitumor efficacy of IGM in a tumor-bearing mouse model via intravenous tail vein injection The therapeutic efficacy of the drug following intravenous administration and systemic circulation was evaluated in BALB/c mice bearing 4T1 tumors, with respect to its inhibitory effect on established solid tumors and its capacity to eliminate potential microscopic metastatic lesions. After successful tumor engraftment, the mice were randomized into 7 groups (NC, MOF, GEM, IG, IG + NIR, IGM, and IGM + NIR, n = 5). During the treatment period, tumor volumes and body weights of the mice were monitored. First, IGM@Cy5.5 was used to validate the tumor enrichment efficacy (EPR effect) of the IGM nanomedicine. After successful tumor inoculation, the mice were randomized into 7 groups (NC, MOF, GEM, IG, IG + NIR, IGM, and IGM + NIR, n = 5). Monitoring of tumor volume and mouse body weight was carried out over the entire treatment period. Drugs were administered via tail vein injection (Cy5.5 group and IGM@Cy5.5 group) and time-point tracking was conducted with a small animal in vivo imaging system at multiple time points (1, 2, 4, 6, 12, 24, 36, 48, and 96 h). The results showed that the fluorescence intensity of the IGM@Cy5.5 group was confined solely to the tumor site, gradually increased, peaked at 6 h, and then slowly declined, with a significant signal still detectable at 24h (Fig. 7a). In contrast, after tail vein injection of the Cy5.5 group, the fluorescence was dispersed, appearing over a larger area outside the tumor. Its intensity was highest initially and then progressively decreased, almost disappearing by 12h. Quantitative analysis of fluorescence intensity revealed that both the enrichment effect and intensity of the IGM@Cy5.5 drug at the tumor site were higher than those of the Cy5.5 group (Fig. 7b). Validation of Drug Enrichment Efficacy via Tumor-bearing Experiment Combined with Tail Vein Injection. (a) In vivo fluorescence imaging showing the status of tumors at 96 h post intravenous injection of free Cy5.5 and IGM@Cy5.5 nanocarriers (n = 3). (b) Quantitative analysis of the dynamic fluorescence intensity of Cy5.5 at the tumor site (n = 3). (c) Fluorescence distribution of Cy5.5 in tumors and major healthy organs 24 h after administration (n = 3). (d) Cy5.5 level in healthy organs and tumors at the end of the biodistribution study (n = 3). (e) Schematic diagram of the in vivo therapeutic regimen in mice. (f) Infrared thermal images visualizing the temperature changes at the tumor site within 2 min of laser irradiation, administered 6 h post tail vein injection of drugs in the NC + NIR, IG + NIR, and IGM + NIR groups. (g) Tumor growth curves of each group after different treatments (n = 5). (h) Body weight data of mice in each group (n = 5). (i) Photographs of excised tumors from mice in different treatment groups. (j) Tumor size tracking curves for each group after different treatments. Simultaneously, ex vivo fluorescence imaging and quantitative analysis of isolated organs were performed 24 h post-administration of IGM to verify the in vivo biodistribution, with results presented in Fig. 7c and d. The IGM@Cy5.5 group exhibited markedly stronger fluorescence signals in tumor tissues, whereas the fluorescence signals in the liver, kidney, and other organs were significantly weaker compared to the free Cy5.5 group. Quantitative results demonstrated that the fluorescence intensity at the tumor site in the IGM@Cy5.5 group was significantly higher than that in the free Cy5.5 group (a 3.19-fold increase), while the fluorescence intensities in the liver and kidney were lower than those of the Cy5.5 group. These findings confirm that IGM can reduce non-specific organ uptake and achieve high accumulation at the tumor site. This indicates that IGM possesses a passive enrichment effect at the tumor site, which benefits from the EPR effect of the nanomaterials. The in vivo photothermal capability of the laser group was validated by monitoring tumor temperature elevation following exposure to 660 nm laser irradiation (1 W/cm2, 2 min) administered 6 h post-drug administration (Fig. 7f). In the IG + NIR group, despite the lack of efficient accumulation, a relatively high drug concentration was still maintained at the tumor site, resulting in a modest temperature increase (<40 °C). However, the heated area did not cover the entire tumor region. In contrast, the IGM + NIR group exhibited a pronounced temperature rise with clearly demarcated boundaries that fully encompassed the tumor, reaching 52.7 °C within 2 min. These results further demonstrate the positive role of the MOF carrier in promoting drug accumulation. The tumor volume in the saline-treated negative control (NC) group grew the fastest, and the MOF group displayed a growth trend similar to that of the NC group, indicating that intravenous injection of the MOF carrier alone had almost no inhibitory effect on the tumors (Fig. 7g–j). The IG group showed poor tumor suppression due to the lack of chemotherapeutic drug release. The GEM group fully exerted its chemotherapeutic effect, leading to inhibited tumor volume; however, the non-targeted nature of intravenous injection resulted in a less prominent therapeutic outcome. Both the IG and IG + NIR groups still failed to achieve significant enrichment at the tumor site, which limited drug release upon laser irradiation and consequently restricted the efficacy of photothermal and photodynamic therapy, resulting in a therapeutic effect inferior to that of the GEM group. In contrast, the IGM group, benefiting from effective drug enrichment and the synergy of ferroptosis and pyroptosis, demonstrated a superior therapeutic level compared to the GEM group. Furthermore, the IGM + NIR group achieved a tumor inhibition rate of 90.6%, far exceeding that of all other treatment groups, with tumor volume significantly reduced or even eliminated. During the treatment period, body weight of the mice showed a gradual upward trend, and there were no marked differences across the treatment groups, except the GEM group exhibited a lower body weight (Fig. 7h). This outstanding efficacy is attributed to high-concentration drug retention and the combined photothermal and photodynamic effect. Fig. 7i presents photographs of the dissected tumor sizes from each group. The results collectively demonstrate that the IGM material can significantly accumulate at the tumor site and exhibit excellent therapeutic efficacy upon laser irradiation, which is attributed to the synergistic enhancement of the EPR effect and multimodal cell death induction. The results of H&E staining within the principal visceral organs of the animals in each treatment group showed that mice in the GEM group presented significant interstitial hyperplasia and inflammation in the lungs, as well as renal tubular lumen dilatation and inflammation in the kidneys (Fig. S9). In contrast, no obvious inflammatory responses were observed in the IGM group and the laser group, and low-level Ki67 expression was detected in the IGM + NIR group. These results illustrate that IGM can accumulate at the tumor site, avoiding the significant systemic toxicity seen in the GEM group, while demonstrating high-level therapeutic efficacy. Dual-tumor mouse experiment to validate the immune activation effect of IGM The dual-tumor experiment is an animal model design commonly used in tumor immunotherapy research, in which, only the primary tumor is treated, and the response of a distant, untreated tumor is observed to evaluate the systemic immune activation effect of the therapy [63]. Therefore, a dual-tumor model mouse was employed to validate the immune activation effect of IGM + NIR. A total of five groups were established: normal saline (NC), NC + NIR, GEM, IGM, and IGM + NIR (n = 5). The NC group served to exclude the influence of basal immunity, the NC + NIR group controlled for non-specific photophysical stimulation, the GEM group simulated the efficacy of clinical chemotherapy, and the comparison between the IGM and IGM + NIR groups aimed to clarify the light-controlled synergistic enhancement. Specifically, immune activation was assessed by tracking tumor volume changes and detecting immune-related markers in tumor tissues. The treatment schedule is depicted in Fig. 8a. The post-dissection bilateral tumor comparison images (Fig. 8b) and the results of Ki67 staining and H&E staining (Fig. S10) clearly demonstrate the differences in tumor size and therapeutic efficacy among the various treatment groups. Meanwhile, no substantial pathological lesions were detected in the major organs of mice upon H&E staining (Fig. S11). Evaluation of immune activation via a bilateral tumor-bearing mouse model using the IGM material. (a) Schematic diagram of the in vivo therapeutic regimen. (b) Growth curves of primary tumors in different treatment groups (n = 5). (c) Growth curves of distant tumors in different treatment groups (n = 5). (d) Representative photographs showing the sizes of primary and distant tumors across treatment groups. (e-f) Flow cytometry plots and statistical analysis of mature dendritic cells in the spleen of mice from each group. (g-h) Flow cytometry plots and statistical analysis of mature dendritic cells in the primary tumors of mice from each group. (i-j) Flow cytometry plots and statistical analysis of mature dendritic cells in the distant tumors of mice from each group. (k-l) Flow cytometry plots depicting CD4+ T cell and CD8+ T cell infiltration within tumors across groups. (m-n) Statistical analysis of tumor-infiltrating CD4+ T cells and CD8+ T cells. (o) Levels of TNF-α in tumor homogenates from each group of mice. (p) Levels of IFN-γ in tumor homogenates from each group of mice. The immune activation effect was judged by monitoring the volume changes of the distant, untreated tumors (Fig. 8c). The results showed that tumor proliferation in the IGM + NIR group was significantly inhibited by day six. In comparison, no marked difference in distant tumor volume was observed among the NC, NC + NIR, and GEM groups. The IGM group showed a partial inhibitory trend but could only delay tumor growth to a limited extent. A visual comparison of the excised bilateral tumors clearly revealed differences in tumor size and therapeutic efficacy among the groups (Fig. 8d). These findings indicate that the IGM + NIR group exhibits excellent immune activation capability with systemic effects. Simultaneously, they demonstrate that laser irradiation serves as a key regulatory factor for IGM in activating systemic immunity in mice. The suppression of distal tumors is achieved through IGM combined with NIR-induced immune activation. This effect is attributed to laser-triggered immunogenic cell death and the release of immunostimulatory cytokines via the cGAS–STING pathway, which promote dendritic cell maturation and antigen presentation, ultimately leading to marked infiltration of cytotoxic CD8+ T cells. The degree of dendritic cells (DCs) maturation directly determines both the effectiveness of antigen presentation and the polarization of immune responses. Therefore, we performed flow cytometric analysis of DC maturation rates in the spleen and bilateral tumors of mice from each treatment group. Given the high technical complexity and strict cell viability constraints of freshly isolated tumor-infiltrating lymphocytes, which precluded a larger sample size, a post-hoc power analysis was conducted using G*Power 3.1 to rigorously evaluate the sufficiency of the sample size. The analysis was based on the effect size of the primary endpoint (distant tumor volume). The calculated effect size (Cohen's d) was 3.94 (mean difference = 252.48 mm3, pooled SD = 64.04), which substantially exceeds the conventional threshold for a large effect (d = 0.8). With α = 0.05 (two-sided) and n = 3 per group, the achieved statistical power exceeded 0.94. The power analysis confirms adequate statistical power to identify the observed treatment effect, verifying sufficient sample size and minimizing false-negative risks. The results showed that compared to the IGM group, the proportion of CD80+/CD86+ DCs in the spleen of the IGM+NIR group was significantly increased (60.75%, P 0.0003) (Fig. 8e and f). A significant increase in the proportion of CD80+/CD86+ DCs was also observed in both the primary tumor (64.69%, P = 0.0005) (Fig. 8g and h) and the distant tumor (83.18%, P = 0.0004) (Fig. 8i and j). This indicates that the IGM + NIR group possesses a high capability to induce DC maturation, laying the foundation for activating adaptive immunity. To quantify the infiltration of cytotoxic T lymphocytes (CD8+ T cells) in both primary and distant tumors, we performed immunofluorescence and flow cytometric analysis on tumor tissues. Fig. 8k, l shows representative flow cytometry results of cytotoxic CD8+ T cell infiltration in primary and distant tumors. The results demonstrated that the infiltration intensity of CD8+ T cells within the tumor microenvironment of both sites in the IGM+NIR group was significantly higher than that in the control groups. Specifically, the absolute density of CD8+ T cells in the primary tumor of the IGM+NIR group (20.4 ± 0.8) increased by 94% compared to the NC group (10.3 ± 0.2) (p < 0.001) and by 47.8% compared to the IGM-only group (13.8 ± 0.3) (Fig. 8m). Similarly, the absolute density in the distant tumor (20.5 ± 0.4) increased by 94% compared to the NC group (10.3 ± 0.4) (p < 0.001) and by 75.2% compared to the IGM-only group (11.7 ± 0.1) (Fig. 8n). This indicates that IGM + NIR can significantly enhance CD8+ T cell infiltration, thereby activating the immune system to execute tumor killing. The gating strategy for flow cytometry analysis is detailed in Figs. S12 and S13. We further measured the concentrations of TNF-α (Fig. 8o) and IFN-γ (Fig. 8p) in homogenates of the proximal tumor tissue. Compared to the IGM group, the levels of TNF-α and IFN-γ in the IGM + NIR group were significantly elevated (by 86.75% and 66.67%, respectively), indicating a significant activation of the local tumor immune response. Therefore, combined with the cellular-level measurement of DAMPs, we infer that the effective triggering of the photoresponsive switch initiates with the stimulated burst release of DAMPs from tumor cells. This process synergizes with the activation of the cGAS-STING pathway, promoting DC maturation, antigen presentation, T cell activation, and targeted tumor cell killing, forming a reinforcing cycle. This also demonstrates that the IGM material can achieve controllable immune activation capability based on the presence or absence of laser irradiation. Conclusion In summary, this study develops a novel light-responsive nanodiagnostic system (IGM) that addresses chemotherapy resistance and immunosuppression in TNBC by spatiotemporally activating apoptosis, ferroptosis, and pyroptosis. IGM dissociates in the acidic, GSH-rich TME to release iron ions, and upon NIR irradiation, delivers GEM with ROS and heat generation. It induces DNA damage, suppresses GSH/GPX4, activates inflammatory pathways, and triggers ICD and mtDNA-driven cGAS-STING-IRF3 activation, promoting DC maturation and CD8+ T cell infiltration. In vivo, IGM shows favorable targeting and biosafety, achieving potent single-tumor inhibition and 92.7% distal tumor suppression in bilateral models. This work offers a precise, multimodal nanoplatform integrating phototherapy, chemotherapy, and immunotherapy to overcome resistance and immune evasion in TNBC, supporting clinical translation. CRediT authorship contribution statement Pan Zhang: Conceptualization, Data curation, Investigation, Resources, Validation, Writing – original draft. Minglun Liu: Conceptualization, Investigation, Software, Supervision, Writing – original draft. Lei Huang: Data curation, Methodology, Software, Validation. Zijie Zhao: Conceptualization, Investigation, Resources. Qianqian Zhang: Data curation, Investigation. Yunhao Li: Data curation, Formal analysis, Investigation. Yuncong Chen: Conceptualization, Funding acquisition, Supervision, Writing – review & editing. Lili Liang: Conceptualization, Funding acquisition, Project administration, Supervision, Writing – review & editing. Declaration of competing interest The authors declare no competing financial interest. Acknowledgments This work was financially supported by the National Natural Science Foundation of China (22377050), Bengbu Medical University Research Project via "Open Bidding for Key Tasks" (2025byjbgs024), Key Research Project of Anhui Provincial Department of Education (2025AHGXZK40720), Graduate scientific research project of Anhui Universities (2024cxcysj169). Footnotes Supplementary data to this article can be found online at https://doi.org/10.1016/j.mtbio.2026.103598. Contributor Information Yuncong Chen, Email: chenyc@nju.edu.cn. Lili Liang, Email: liangjyt@163.com. Supplementary data The following is the Supplementary data to this article: Multimedia component 1 Data availability Data will be made available on request. References Associated Data Supplementary Materials Multimedia component 1 Data Availability Statement Data will be made available on request.